The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics.
Sigdel TK, Salomonis N, et al.Molecular & Cell Proteomics 2014; 13 (2): 621-631
Aims
To investigate urine protein biomarkers in renal transplant patients with biopsy confirmed allograft injury using iTRAQ-based proteomic discovery and targeted ELISA.
Interventions
Urine samples were randomly allocated to undergo proteomics discovery or ELISA validation.
Participants
Urine samples from 262 kidney transplant recipients.
Outcomes
The outcomes included peptide and protein identifications for kidney transplant urine, identification of chronic allograft injury enriched proteins, comparison and functional analysis of distinct forms of renal transplant injury and ELISA validation of acute rejection specific proteins.
Follow-up
Not reported.
CET Conclusions
This is a very interesting study from the Minnie Sarwal group in California looking at the urine of recipients of a renal allograft with biopsy confirmed allograft injury. The urine samples were split into a training set and a validation set, both having over a hundred patients. 389 proteins were measured, these being chosen to display differential abundances across urine specimens in the different types of graft injury. The technology has been validated and it is apparent that this method provides an effective strategy for biomarker discovery in the urine of transplant patients with injury to the transplanted kidney. Large well designed clinical trials of the appropriate biomarkers will now be needed to define the utility of these protein panels in predicting risk in renal transplant patients.
Quality notes
This is a training and validation paper – quality assessment not appropriate.
Trial registration
Not reported.